ArticlePatient preference and adherence2025
Identifying Causes of Subcutaneous Immunotherapy Non-Adherence in Patients with Allergic Rhinitis: A Cross-Sectional Study.
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the reasons for discontinuation of subcutaneous immunotherapy (SCIT) in patients with allergic rhinitis (AR) and to inform strategies for improving treatment adherence. Materials and Methods: In this single-center retrospective cross-sectional study, 794 AR patients (age 1-60 years) who initiated standardized SCIT with house dust mite extracts at Shenzhen University General Hospital between December 2019 and July 2023 were included. SCIT followed a structured dose-escalation and maintenance protocol: weeks 1-4, 0.1-0.8 mL (50 TU/mL); weeks 5-8, 0.1-0.8 mL (500 TU/mL); weeks 9-14, 0.1-1.0 mL (5000 TU/mL); weeks 14-152, monthly 1.0 mL (5000 TU/mL). Symptom severity was assessed using a visual analogue scale (VAS) at baseline and at 6 months, 1, 2, and 3 years; <20% VAS reduction and/or patient-reported insufficient improvement after ≥12 months defined "unsatisfactory efficacy". Structured telephone follow-up was used, with caregivers interviewed for pediatric patients. All patients provided detailed contact information; no loss to follow-up occurred. Results: Fifty-eight patients (7.30%) discontinued SCIT (27 males, 31 females; mean age 14.71 ± 10.76 years). Leading reasons were relocation for education, work, or travel (53.45%), perceived lack of efficacy (17.24%), limited time (8.62%), and pregnancy/gynecological conditions (6.90%). Females were more likely to discontinue due to relocation, males due to unsatisfactory efficacy; age and comorbidities were not significantly associated with dropout. Conclusion: SCIT discontinuation was mainly driven by relocation, treatment expectations, and logistical factors, with gender-specific patterns. Tailored pre-treatment counseling, assessment of lifestyle and reproductive plans, and strategies to maintain continuity of care may reduce dropout and improve long-term adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.